

AFLURIA® QUADRIVALENT (Influenza Vaccine) Coding and Billing



Be sure to use the Current Procedural Terminology (CPT) code for the AFLURIA QUADRIVALENT administered.

Code for the AFLURIA QUADRIVALENT vaccine administered

2020-2021 NDC Carton ¹	2020-2021 NDC Unit-of-Use ¹	Presentation and Indication ¹	Product Billing CPT Code	Description ¹
33332-220-20	33332-220-21	0.25 mL pre-filled syringe (6-35 months)	90685	Influenza vaccine, quadrivalent (IIV4), split virion, contains no preservative, 0.25 mL dosage, for intramuscular use
33332-320-01	33332-320-02	0.5 mL pre-filled syringe (36 months and older)	90686	Influenza vaccine, quadrivalent (IIV4), split virion, contains no preservative, 0.5 mL dosage, for intramuscular use
33332-420-10	33332-420-11	5 mL multi-dose vial* (6-35 months)	90687 (0.25 mL dose)	Influenza vaccine, quadrivalent (IIV4), split virion, 0.25 mL dosage, for intramuscular use
		5 mL multi-dose vial* (36 months and older)	90688 (0.5 mL dose)	Influenza vaccine, quadrivalent (IIV4), split virion, 0.5 mL dosage, for intramuscular use

*The number of needle punctures should not exceed 20 per multi-dose vial.
NDC=National Drug Code

Note: Some payers may require use of NDC codes. If so, determine if the payer requires the carton NDC or the unit-of-use NDC, and then determine if the payer requires the 10-digit or 11-digit format. If 11-digit, add a leading zero to the middle section of numbers.

Code for the administration of AFLURIA QUADRIVALENT

Report the appropriate administration code in addition to the CPT code for AFLURIA QUADRIVALENT.²

For most payers, use the appropriate CPT code based on age and counseling provided. Note: Medicare (and some other payers) requires use of the Healthcare Common Procedure Coding System (HCPCS) code, G0008, for administration of preventive vaccines, including influenza, regardless of age.

Include the appropriate *International Classification of Diseases, Tenth Revision (ICD-10)* diagnosis code

Report the ICD-10 diagnosis code, Z23, indicating an encounter for vaccine administration. The ICD-10 diagnosis code should be linked to both the vaccine and the administration code.³

Determine if modifier 25 is appropriate

When AFLURIA QUADRIVALENT is administered on the same date as a significant and separately identifiable Evaluation and Management (E/M) visit, apply modifier 25 to the E/M CPT code, denoting a “significant and separately identifiable” service from the vaccine and vaccine administration service.⁵

CPT Code ²	Description
90460	Immunization administration through 18 years of age (includes any route of administration) with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered
90461 (add-on code)	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (list separately in addition to code for primary procedure)
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) ⁴ NOTE: Report this code for immunization administration of any vaccine that is not accompanied by face-to-face physician or other qualified health care professional counseling the patient and/or family, or for patients over 18 years of age. ⁵
HCPCS Code ²	Description
G0008	Seasonal influenza virus vaccine administration
ICD-10 Code ³	Description
Z23	Encounter for immunization

Please see Important Safety Information on next page, and the US full Prescribing Information for AFLURIA QUADRIVALENT [here](#).

Questions?



Call flu360 | Support
855-358-8966, option 3

AFLURIA® QUADRIVALENT (Influenza Vaccine)

Indication and Important Safety Information



INDICATION AND USAGE

AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.

AFLURIA QUADRIVALENT is approved for use in persons 6 months of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

AFLURIA QUADRIVALENT is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine.

WARNINGS AND PRECAUTIONS

If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give AFLURIA QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

If AFLURIA QUADRIVALENT is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be diminished.

Vaccination with AFLURIA QUADRIVALENT may not protect all individuals.

ADVERSE REACTIONS

AFLURIA QUADRIVALENT administered by needle and syringe:

In adults 18 through 64 years, the most commonly reported injection-site adverse reaction was pain ($\geq 40\%$). The most common systemic adverse events were myalgia and headache ($\geq 20\%$).

In adults 65 years of age and older, the most commonly reported injection-site adverse reaction was pain ($\geq 20\%$). The most common systemic adverse event was myalgia ($\geq 10\%$).

In children 5 through 8 years, the most commonly reported injection-site adverse reactions were pain ($\geq 50\%$), redness and swelling ($\geq 10\%$). The most common systemic adverse event was headache ($\geq 10\%$).

In children 9 through 17 years, the most commonly reported injection-site adverse reactions were pain ($\geq 50\%$), redness and swelling ($\geq 10\%$). The most common systemic adverse events were headache, myalgia, and malaise and fatigue ($\geq 10\%$).

In children 6 months through 35 months of age, the most commonly reported injection-site reactions were pain and redness ($\geq 20\%$). The most common systemic adverse events were irritability ($\geq 30\%$), diarrhea and loss of appetite ($\geq 20\%$).

In children 36 through 59 months of age, the most commonly reported injection site reactions were pain ($\geq 30\%$) and redness ($\geq 20\%$). The most commonly reported systemic adverse events were malaise and fatigue, and diarrhea ($\geq 10\%$).

The safety experience with AFLURIA (trivalent formulation) is relevant to AFLURIA QUADRIVALENT because both vaccines are manufactured using the same process and have overlapping compositions:

In adults 18 through 64 years of age, the most commonly reported injection-site adverse reactions with AFLURIA (trivalent formulation) when administered by the PharmaJet Stratis Needle-Free Injection System were tenderness ($\geq 80\%$), swelling, pain, redness ($\geq 60\%$), itching ($\geq 20\%$) and bruising ($\geq 10\%$). The most common systemic adverse events were myalgia, malaise ($\geq 30\%$), and headache ($\geq 20\%$).

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus USA Inc. at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Before administration, please see the full US Prescribing Information for AFLURIA QUADRIVALENT [here](#).

AFLURIA® QUADRIVALENT is a registered trademark of Seqirus UK Limited or its affiliates.

PharmaJet® and STRATIS® are registered trademarks of PharmaJet.

Information on reimbursement is provided as a courtesy. Due to the rapidly changing nature of the law, Medicare payment policy, and/or reliance on information provided by outside sources, the information provided herein does not constitute a guarantee or warranty that reimbursement will be received or that the codes identified herein are or will remain applicable. This information is provided “as is” and without any other warranty or guarantee, expressed or implied, as to completeness or accuracy, or otherwise.

Providers must confirm or clarify coding and coverage from their respective payers, and are responsible for accurate reporting of products in accordance with particular payer requirements.

References: **1.** AFLURIA QUADRIVALENT. Package insert. Seqirus Inc; 2020. **2.** Centers for Medicare & Medicaid Services. Medicare Part B immunization billing: seasonal influenza virus, pneumococcal, and hepatitis B. Accessed June 5, 2020. https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/downloads/qv_immun_bill.pdf **3.** Hughes C. ICD-10 simplifies preventive care coding, sort of. *Fam Pract Manag.* 2014;21(4):OA1-OA4. **4.** American Academy of Pediatrics. Coding for pediatric preventive care 2020. Accessed June 5, 2020. https://www.aap.org/en-us/Documents/coding_preventive_care.pdf **5.** American College of Cardiology. Appropriate use of modifier 25. Accessed June 5, 2020. <https://www.acc.org/tools-and-practice-support/practice-solutions/coding-and-reimbursement/appropriate-use-of-modifier-25> **6.** American Academy of Family Physicians. Coding for vaccine administration. Accessed September 24, 2020. <https://www.aafp.org/family-physician/practice-and-career/getting-paid/coding/vaccine-administration.html>.

AFLURIA® QUADRIVALENT, flu360™, and WE'VE GOT FLU COVERED™ are trademarks of Seqirus UK Limited or its affiliates.

Manufactured by: Seqirus Inc., 475 Green Oaks Parkway, Holly Springs, NC 27540, USA

Distributed by: Seqirus USA Inc., 25 Deforest Avenue, Summit, NJ 07901, USA

©2020 Seqirus USA Inc. October 2020 US/FLU360/0620/0030a(1)

